Executive Officer, and as a member of the board of directors, from May 2004 until its acquisition in March 2014 by Mallinckrodt Pharmaceuticals, Inc. Prior to joining Dura Pharmaceuticals, Inc.,
Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder currently serves on the board of directors of Cidara Therapeutics, Inc., a
public biotechnology company, Collegium Pharmaceuticals, a public specialty pharmaceutical company, and Biocom, a regional life science trade association, where he is Chairman Emeritus and a member of the executive committee. Mr. Schroeder
holds a Bachelors degree in management from Rutgers University.
We believe Mr. Schroeder is qualified to serve on our board of
directors because of his leadership and broad range of experience in pharmaceutical and life sciences companies.
Vickie
Capps
has served on our board of directors since March 2014. From August 2014 to December 2015, Ms. Capps served as the Executive Director at Eagle Rx, Inc., a provider of pharmacy services to the hospice industry. From July 2002
to December 2013, Ms. Capps was the Chief Financial Officer of DJO Global, Inc. Ms. Capps joined DJO Global, Inc. in 2002. Prior to joining DJO Global, Inc., Ms. Capps served as the Chief Financial Officer of several other public and
private companies. Earlier in her career, Ms. Capps was a Senior Audit and Accounting Professional at Ernst & Young LLP. Ms. Capps is currently a member of the Senior Advisory Board of Consonance Capital Partners
(CCP), a healthcare investment firm, and is a member of the board of directors of CCPs portfolio company, Eagle Rx, Inc. Ms. Capps is also a member of the board of directors of Connecture, Inc., a health care IT company,
OmniGuide, Inc., a private medical device company, and is the chair of its audit committee and a member of its nominating and governance committee. Ms. Capps is also a member of the board of directors and audit committee of NuVasive, Inc., a
medical device company. From December 2013 to August 2015, Ms. Capps served as a member of the board of directors of RF Surgical Systems, Inc., a private medical device company, and as chair of its audit committee, prior to the companys
acquisition by Medtronic plc in August 2015. From 2007 to July 2010, Ms. Capps served as a member of the board of directors of SenoRx, Inc., a surgical products company, prior to its acquisition by C. R. Bard, Inc. in July 2010. In addition,
Ms. Capps serves as a member of the board of directors of the San Diego State University Research Foundation and is a member of its audit committee and its finance and investment committee. Ms. Capps also serves on the board of directors
of the Santaluz Club and is a member of its finance committee. Ms. Capps is a California Certified Public Accountant and was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. Ms. Capps holds a
Bachelors degree in Business Administration/Accounting from San Diego State University.
We believe Ms. Capps is qualified to
serve on our board of directors because of her exceptionally strong skill set consisting of corporate finance, accounting, operations, investor relations, capital markets and strategic business development.
Iain McGill
has served on our board of directors since August 2016. Mr. McGill currently serves as Senior Vice
President of Jazz Pharmaceuticals Europe and Rest of World for Jazz Pharmaceuticals Public Limited Company, an international biopharmaceutical company, since March 2015. From March 2014 to March 2015, Mr. McGill served as Head of EUSA
Pharma and Senior Vice President, Jazz Pharmaceuticals, and as Chief Commercial Officer, EUSA Pharma, a specialty pharmaceutical company, from June 2012 to March 2014, when he joined Jazz Pharmaceuticals in connection with its acquisition of EUSA
Pharma. From October 2011 to June 2012, Mr. McGill served as Chief Commercial Officer at EUSA Pharma (Europe) Ltd. From August 2010 to September 2011, he served as President Europe, International & Global Marketing of EUSA
Pharma (Europe) Ltd, and from January 2010 to July 2010, as President of Europe. From 2006 to 2009, Mr. McGill served as Vice President and Global Business Manager at Wyeth, a pharmaceutical company acquired by Pfizer Inc. Mr. McGill
holds a Bachelor of Science degree in Biochemistry from the University of London.
We believe Mr. McGill is qualified to serve on our
board of directors because of his leadership experience in the biotechnology and pharmaceutical industries.
-10-